Stellar Biotechnologies Inc  

(Public, CVE:KLH)   Watch this stock  
Find more results for cve:klh
0.650
+0.060 (10.17%)
Delayed:   2:39PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.58 - 0.66
52 week 0.19 - 0.72
Open 0.60
Vol / Avg. 239,927.00/76,967.00
Mkt cap 33.42M
P/E     -
Div/yield     -
EPS -0.12
Shares 51.41M
Beta 1.73
Inst. own     -

Key stats and ratios

Q4 (Nov '12) 2012
Net profit margin -661.76% -1816.71%
Operating margin -661.76% -1816.43%
EBITD margin - -2204.35%
Return on average assets -165.87% -165.12%
Return on average equity -400.12% -265.43%
Employees 6 -
Carbon Disclosure Rating - -

Address

332 E. Scott Street
PORT HUENEME, CA 93041
United States - Map
+1-604-6719411 (Phone)
+1-604-5241660 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Stellar Biotechnologies, Inc. (Stellar), is engaged in production of purified Keyhole Limpet Hemocyanin (KLH) for use in a new class of medicines known as therapeutic vaccines and in immunological research. The Company is the only company dedicated solely to developing and commercializing KLH products. KLH is a component for cancer vaccines and anticipated therapeutic vaccines, including those for lymphoma, sarcoma, small cell lung cancer, Alzheimer�s disease, rheumatoid arthritis, lupus, and Post Traumatic Stress Disorder chemical dependencies. The Company provides cGMP KLH products to the biopharmaceutical and vaccine development markets. The Company's products include: stellar KLH protein and stellar KLH ELISA Kits.

Officers and directors

Frank R Oakes President, Chief Executive Officer, Director
Scott Davis Chief Financial Officer
Darrell H. Brookstein Executive Vice President - Corporate Development & Finance, Secretary, Director
Herbert S. Chow Ph.D. Chief Technology Officer
Daniel E. Morse Ph.D. Director
Gregory T. Baxter Ph.D. Independent Director
David L. Hill Ph.D. Independent Director
Mayank D. Sampat Independent Director